| 2.49 0.16 (6.87%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.06 |
1-year : | 3.57 |
| Resists | First : | 2.61 |
Second : | 3.06 |
| Pivot price | 2.35  |
|||
| Supports | First : | 2.32 |
Second : | 2.13 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.37 |
| MA(100) : | 2.66 |
MA(250) : | 6.43 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 47.9 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 15.21 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALZN ] has closed below upper band by 21.0%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.56 | 2.56 - 2.58 |
| Low: | 2.3 - 2.31 | 2.31 - 2.33 |
| Close: | 2.47 - 2.49 | 2.49 - 2.51 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Thu, 09 Oct 2025
Alzamend Neuro Issues New Common Stock Shares - TipRanks
Wed, 08 Oct 2025
Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222 - Investing.com
Mon, 06 Oct 2025
Ault Milton C III sells Alzamend Neuro (ALZN) stock worth $296k - Investing.com
Mon, 28 Jul 2025
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewswire
Wed, 23 Jul 2025
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - Yahoo Finance
Mon, 16 Jun 2025
Fast-Tracked: $5M Investment Accelerates 5 Phase II Trials for Alzheimer's and Mental Health Breakthroughs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 210 (K) |
| Shares Short P.Month | 137 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -97.5 % |
| Return on Equity (ttm) | -302.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -2.12 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|